Observe Medical ASA: Key information relating to subsequent offering _ repair issue
NOT FOR DISTRIBUTION, PUBLICATION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, HONG KONG, SOUTH AFRICA OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION, PUBLICATION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.
Oslo, 24 June 2024
Reference is made to the stock exchange announcement by Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) earlier today, regarding the placement of a private placement (the "Private Placement"), where it was also stated that the board of directors intends to carry out a subsequent offering (the "Subsequent Offering") directed at shareholders in the Company as of 24 June 2024 (as registered in the VPS on 26 June 2024) who (i) were not allocated shares in the Private Placement and (ii) are not domiciled in a jurisdiction where such offering would be unlawful, or, would, in jurisdictions other than Norway, require any prospectus, filing, registration or similar action. Completion of the Subsequent Offering will be subject to (i) approval from the Company's extraordinary general meeting, (ii) completion of the Private Placement and (iii) the publication of a prospectus by the Company that is approved by the Financial Supervisory Authority of Norway.
Date on which the terms and conditions of the repair issue were announced: 24 June 2024
Last day including right: 24 June 2024
Ex-date: 25 June 2024
Record date: 26 June 2024
Date of approval: 17 July 2024
Maximum number of new shares: 32,500,000
Subscription price: NOK 0.40
For further information, please contact:
Jørgen Mann, Interim CEO Observe Medical
Mobile: +45 408 67 558
E-mail: [email protected]
Johan Fagerli, CFO Observe Medical
Mobile: +47 958 12 765
E-mail: [email protected]
This information is published in accordance with the requirements of the Continuing Obligations.